These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1539328)

  • 1. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.
    Friman S; Persson H; Scherstén T; Svanvik J; Karlberg I
    Transplant Proc; 1992 Feb; 24(1):389-90. PubMed ID: 1539328
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant ursodeoxycholic acid prevents acute rejection in liver transplant recipients.
    Henriksson BA; Persson H; Friman S; Wängberg B; Svanvik J; Karlberg I
    Transplant Proc; 1991 Jun; 23(3):1971. PubMed ID: 2063453
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.
    Friman S; Persson H; Scherstén T; Svanvik J; Karlberg I
    Transpl Int; 1992; 5 Suppl 1():S187-9. PubMed ID: 14621771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
    Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
    Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.
    Barnes D; Talenti D; Cammell G; Goormastic M; Farquhar L; Henderson M; Vogt D; Mayes J; Westveer MK; Carey W
    Hepatology; 1997 Oct; 26(4):853-7. PubMed ID: 9328304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?
    Keiding S
    Hepatology; 1998 Jun; 27(6):1748-9. PubMed ID: 9620354
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence that ursodeoxycholic acid prevents steroid-resistant rejection in adult liver transplantation.
    Clavien PA; Sharara AI; Camargo CA; Harland RC; Fitz JG
    Clin Transplant; 1996 Dec; 10(6 Pt 2):658-62. PubMed ID: 8996761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of OKT3 for late acute rejection in liver transplantation.
    Samuel D; Gugenheim J; Canon C; Saliba F; Bismuth H
    Transplant Proc; 1990 Aug; 22(4):1767-8. PubMed ID: 2117804
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
    Elkashab M; Reizig M; Greig PD; Cameron R; Phillips MJ; Chung S; Cattral M; Levy G
    Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
    [No Abstract]   [Full Text] [Related]  

  • 10. A possible role of ursodeoxycholic acid in liver transplantation.
    Friman S; Svanvik J
    Scand J Gastroenterol Suppl; 1994; 204():62-4. PubMed ID: 7824880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection.
    Bährle S; Szabó G; Stiehl A; Theilmann L; Dengler TJ; Zimmermann R; Kübler W
    J Heart Lung Transplant; 1998 Jun; 17(6):592-8. PubMed ID: 9662095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients.
    Assy N; Adams PC; Myers P; Simon V; Ghent CN
    Gut; 2007 Feb; 56(2):304-6. PubMed ID: 17303606
    [No Abstract]   [Full Text] [Related]  

  • 13. [Does acute graft rejection modify subsequent function of a transplanted liver?].
    Seiler CA; Renner EL; Czerniak A; Büchler MW
    Swiss Surg; 1995; (4):186-7. PubMed ID: 9156818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of reduced-size liver transplantation on rejection and liver allograft outcome in the pediatric population.
    Cacciarelli TV; So SK; Egawa H; Cox K; Esquivel CO
    Transplant Proc; 1995 Feb; 27(1):1239-40. PubMed ID: 7878864
    [No Abstract]   [Full Text] [Related]  

  • 15. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of FK 506 for treatment of chronic rejection after liver transplantation.
    Winkler M; Ringe B; Gerstenkorn C; Rodeck B; Gubernatis G; Wonigeit K; Pichlmayr R
    Transplant Proc; 1991 Dec; 23(6):2984-6. PubMed ID: 1721334
    [No Abstract]   [Full Text] [Related]  

  • 17. Ursodeoxycholic acid reduces acute rejection in heart allografted rats.
    Friman S; Mjörnstedt L; Persson H; Karlberg I; Olausson M
    Transplant Proc; 1992 Feb; 24(1):344-5. PubMed ID: 1539308
    [No Abstract]   [Full Text] [Related]  

  • 18. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation.
    Pageaux GP; Blanc P; Perrigault PF; Navarro F; Fabre JM; Souche B; Domergue J; Larrey D; Michel H
    J Hepatol; 1995 Aug; 23(2):119-22. PubMed ID: 7499781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute rejection following liver transplantation: a comparison between methylprednisolone and hydrocortisone.
    Barron PT; Jamieson NV; Calne RY
    Transplant Proc; 1991 Aug; 23(4):2266. PubMed ID: 1871868
    [No Abstract]   [Full Text] [Related]  

  • 20. FK 506 as treatment of late acute rejection in liver transplant patients.
    Rucay P; Samuel D; Farges O; Reynes M; Bismuth H
    Transplant Proc; 1995 Feb; 27(1):1105-6. PubMed ID: 7533354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.